Status:
UNKNOWN
Study of CT and MR in the Lung Cancer
Lead Sponsor:
Henan Cancer Hospital
Conditions:
Lung Cancer Squamous Cell
CT
Eligibility:
All Genders
18-80 years
Brief Summary
Lung cancer is one of the leading causes of cancer-related deaths in China. Despite advances in systemic therapy and improvement nonsurvival rates for patients with advanced lung cancer, morbidity and...
Detailed Description
To explore the value of CT and MR using multiple sequences, including T2-TSE-BLADE, T2 maps StarVIBE, and iShim-DWI in evaluating the driving genes and prediction of response to therapy and OS in pati...
Eligibility Criteria
Inclusion
- Consecutive patients with preoperative pathologically con-firmed lung cancer by endoscopy and preoperative imaging data were included.
- No contraindications for MRI examination. No contraindications for iodinated contrast.
- The patients participate in this study with informed consent.
Exclusion
- The patients couldn't performed MSCT or MR scanning or artefacts affect the evaluation.
- The patients are extremely anxious and uncooperative about surgery or neoadjuvant therapy .
- PatientsThe patients refuse to participate in the project.
- Other situations considered by investigators not meet the inclusion criteria.
Key Trial Info
Start Date :
September 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2023
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT04034667
Start Date
September 1 2019
End Date
December 1 2023
Last Update
April 1 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Henan Cancer Hospital
Zhengzhou, China